Medisys PLC
This article was originally published in The Gray Sheet
Executive Summary
Ipswich, U.K. maker of safety syringes raises approximately $69.9 mil. through placement of 37.6 mil. New Ordinary Shares at about $1.86 per share (based on current exchange rates). A portion of the proceeds from the offering will be used to gear up manufacturing efforts for the Futura safety syringe, for which a 510(k) is pending at FDA (1"The Gray Sheet" July 12, 1999, p. 6). The funds also will be used to develop and acquire additional safety products to complement the Futura line, and to "establish a U.S. sales and marketing infrastructure" for next generation blood glucose monitoring systems slated to debut later this year. Nomura International was underwriter for the offering, and the shares trade on the Alternative Investment Market
You may also be interested in...
Medisys' Futura Plans Include Entry Into Growing U.S. Safety Needle Market
Medisys plc's acquisition of the Futura safety syringe from Adventec would provide the firm with a means to tap into the growing demand in the U.S. for sharps with protective features designed to reduce accidental needlesticks among health care workers.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.